MX2017014844A - Regimen modulador selectivo de los receptores de progesterona (sprm). - Google Patents

Regimen modulador selectivo de los receptores de progesterona (sprm).

Info

Publication number
MX2017014844A
MX2017014844A MX2017014844A MX2017014844A MX2017014844A MX 2017014844 A MX2017014844 A MX 2017014844A MX 2017014844 A MX2017014844 A MX 2017014844A MX 2017014844 A MX2017014844 A MX 2017014844A MX 2017014844 A MX2017014844 A MX 2017014844A
Authority
MX
Mexico
Prior art keywords
uterine
regimen
uterine fibroids
myomas
progesterone receptor
Prior art date
Application number
MX2017014844A
Other languages
English (en)
Inventor
Seitz Christian
Knauthe Rudolf
Zeun Susan
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53180494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017014844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2017014844A publication Critical patent/MX2017014844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención está destinada a una composición farmacéutica que comprende un antagonista receptor de progesterona llamado (11ß,17ß)-17-Hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroe til)estra-4,9-dien-3-ona para el tratamiento y/o la profilaxis de Fibromiomas Uterinos (miomas, leiomioma uterino) que se administra diariamente a un paciente diagnosticado con Fibromiomas Uterinos mediante el seguimiento de un régimen específico. Además, la invención está dirigida a un método para el tratamiento contra los Fibromiomas Uterinos (miomas, leiomioma uterino) y/o para la reducción del tamaño y los síntomas de los Fibromiomas Uterinos (miomas, leiomioma uterino) mediante el seguimiento de un régimen específico al igual que un tratamiento contra el Sangrado Menstrual Abundante (HMB).
MX2017014844A 2015-05-18 2016-05-17 Regimen modulador selectivo de los receptores de progesterona (sprm). MX2017014844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001475 2015-05-18
PCT/EP2016/061037 WO2016184863A1 (en) 2015-05-18 2016-05-17 Selective progesterone receptor modulator (sprm) regimen

Publications (1)

Publication Number Publication Date
MX2017014844A true MX2017014844A (es) 2018-02-19

Family

ID=53180494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014844A MX2017014844A (es) 2015-05-18 2016-05-17 Regimen modulador selectivo de los receptores de progesterona (sprm).

Country Status (19)

Country Link
US (3) US20180155388A1 (es)
EP (2) EP3297635A1 (es)
JP (2) JP2018515551A (es)
KR (1) KR20180004814A (es)
CN (2) CN107635562A (es)
AU (1) AU2016262826A1 (es)
BR (1) BR112017024627A2 (es)
CA (1) CA2986064A1 (es)
CL (1) CL2017002920A1 (es)
EA (2) EA036237B1 (es)
HK (1) HK1245118A1 (es)
IL (1) IL255451A0 (es)
MA (2) MA46298A (es)
MX (1) MX2017014844A (es)
PH (1) PH12017502100A1 (es)
SG (1) SG10201910441PA (es)
TN (1) TN2017000482A1 (es)
TW (1) TW201707708A (es)
WO (1) WO2016184863A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635562A (zh) * 2015-05-18 2018-01-26 拜耳医药股份有限公司 选择性孕酮受体调节剂（sprm）方案
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
EP3701951A4 (en) * 2017-10-26 2020-09-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
JP2001520820A (ja) * 1997-02-03 2001-10-30 エムシーアイ・ワールドコム・インコーポレーテッド 通信システム構造
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
SI2314623T1 (sl) 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
EP2272272B1 (en) 2008-04-30 2016-05-18 Telefonaktiebolaget LM Ericsson (publ) Self-backhauling in lte
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
CA2885795A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
JP6343619B2 (ja) * 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
KR20140077499A (ko) * 2012-12-14 2014-06-24 에스케이하이닉스 주식회사 저항 변화 메모리 장치 및 그 제조방법
NZ712984A (en) * 2013-04-10 2020-07-31 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
EP2983671B1 (en) * 2013-04-11 2018-10-24 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
CN107635562A (zh) 2015-05-18 2018-01-26 拜耳医药股份有限公司 选择性孕酮受体调节剂（sprm）方案
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient

Also Published As

Publication number Publication date
KR20180004814A (ko) 2018-01-12
HK1245118A1 (zh) 2018-08-24
BR112017024627A2 (pt) 2018-07-31
CA2986064A1 (en) 2016-11-24
EA036237B1 (ru) 2020-10-16
EA201990106A1 (ru) 2019-05-31
US10858388B2 (en) 2020-12-08
US20180155388A1 (en) 2018-06-07
US20190211053A1 (en) 2019-07-11
JP2018515551A (ja) 2018-06-14
CN113797210A (zh) 2021-12-17
TN2017000482A1 (en) 2019-04-12
EP3297635A1 (en) 2018-03-28
MA46298A (fr) 2019-07-31
EA035567B1 (ru) 2020-07-08
SG10201910441PA (en) 2020-01-30
JP2021098702A (ja) 2021-07-01
EA201792524A1 (ru) 2018-04-30
IL255451A0 (en) 2017-12-31
CL2017002920A1 (es) 2018-05-18
CN107635562A (zh) 2018-01-26
AU2016262826A1 (en) 2017-11-30
EP3417863A1 (en) 2018-12-26
TW201707708A (zh) 2017-03-01
MA42103A (fr) 2018-03-28
PH12017502100A1 (en) 2018-05-07
WO2016184863A1 (en) 2016-11-24
US20190375783A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
PH12017501934A1 (en) Methods for treating or preventing migraine headache
BR112019006227A2 (pt) métodos de tratamento de leiomioma uterino e endometriose
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
SG11201911599XA (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
PH12021550048A1 (en) Selective estrogen receptor degraders.
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
MY172530A (en) Method for treating gynecological diseases
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
EA201990481A1 (ru) Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
PH12015501458A1 (en) A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal
Nayot Headache: 3 case reports
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
UA100789U (uk) Спосіб лікування пацієнток з аномальними матковими кровотечами на тлі антикоагуляційної терапії
TH163150B (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids